ZMYND17 Activators
ZMYND17 Activators primarily act through modulating various cellular signaling pathways that ZMYND17 is involved in, leading to its enhanced functional activity. For instance, cAMP and Forskolin function through the cAMP/PKA pathway. cAMP is a well-known secondary messenger that can directly activate PKA. Activated PKA can then phosphorylate ZMYND17, enhancing its functional activity. Forskolin enhances the production of cAMP, indirectly leading to ZMYND17 activation through PKA. EGF operates through the Ras/Raf/MAPK/ERK pathway. EGF is known to activate this pathway, leading to the activation of ERK, which can then phosphorylate ZMYND17 to enhance its activity. U0126 indirectly enhances ZMYND17 activity via the ERK pathway.
A group of ZMYND17 activators function through the PI3K/Akt pathway. LY294002, Wortmannin, and Quercetin decrease Akt activity, leading to enhanced ZMYND17 activity. Dactolisib inhibits both PI3K and mTOR, leading to decreased Akt activity and enhanced ZMYND17 activity. Rapamycin also leads to decreased Akt activity and enhanced ZMYND17 activity. Genistein also indirectly enhances ZMYND17 activity by decreasing Akt activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Adenosine 3′,5′-cyclic monophosphate | 60-92-4 | sc-217584 sc-217584A sc-217584B sc-217584C sc-217584D sc-217584E | 100 mg 250 mg 5 g 10 g 25 g 50 g | $116.00 $179.00 $265.00 $369.00 $629.00 $1150.00 | ||
cAMP, a secondary messenger, can directly activate Protein Kinase A (PKA). Following activation, PKA can phosphorylate ZMYND17, enhancing its functional activity. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin stimulates the production of cAMP, which can activate PKA. PKA, in turn, can phosphorylate ZMYND17, leading to its enhanced activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, which can dampen the Akt pathway. A decrease in Akt activity can enhance the activity of ZMYND17. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor which can decrease Akt activity, leading to enhanced ZMYND17 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which can lead to decreased Akt activity. This decrease can indirectly enhance ZMYND17 activity. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $211.00 | 8 | |
Dactolisib inhibits both PI3K and mTOR, leading to decreased Akt activity and enhanced ZMYND17 activity. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Quercetin inhibits PI3K, leading to decreased Akt activity. This decrease can enhance ZMYND17 functional activity. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein inhibits tyrosine kinases, leading to decreased Akt activity. This decrease can indirectly enhance ZMYND17 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor, which can indirectly enhance the activity of ZMYND17 through ERK. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. By inhibiting JNK activity, SP600125 can indirectly enhance ZMYND17 activity. | ||||||